ABSTRACT
Psychiatric disorders are highly prevalent and display considerable clinical and genetic overlap. Dopaminergic and serotonergic neurotransmission have been shown to have an important role in many psychiatric disorders. Here we aim to assess the genetic contribution of these systems to eight psychiatric disorders (ADHD, ANO, ASD, BIP, MD, OCD, SCZ and TS) using publicly available GWAS analyses performed by the Psychiatric Genomics Consortium. To do so, we elaborated four different gene sets using the Gene Ontology and KEGG pathways tools: two ‘wide’ selections for dopamine (DA) and for serotonin (SERT), and two ‘core’ selections for the same systems. At the gene level, we found 67 genes from the DA and/or SERT gene sets significantly associated with one of the studied disorders, and 12 of them were associated with two different disorders. Gene-set analysis revealed significant associations for ADHD and ASD with the wide DA gene set, for BIP with the wide SERT gene set, and for MD with both the core DA set and the core SERT set. Interestingly, interrogation of the cross-disorder GWAS meta-analysis displayed association with the wide DA gene set. To our knowledge, this is the first time that these two neurotransmitter systems have systematically been inspected in these disorders. Our results support a cross-disorder contribution of dopaminergic and serotonergic systems in several psychiatric conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Major financial support for this research was received by BC from the Spanish Ministerio de Ciencia, Innovacion y Universidades (RTI2018-100968-B-100), Ministerio de Economia y Competitividad (SAF2015-68341-R) and AGAUR/Generalitat de Catalunya (2017-SGR-738). The research leading to these results has also received funding from the European Union H2020 Program [H2020/2014-2020] under grant agreements 667302 (CoCA), 643051 (MiND) and 728018 (Eat2beNICE) by BC and Federal Ministry of Education and Research (BMBF, grant number: 01EE1404A) by AR. BT and JC-D were supported by the H2020 CoCA project, and NF-C by Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER) and by an EMBO short-term fellowship (ASTF 573-2016). The authors declare no conflict of interests. This publication reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains. The authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the University of Barcelona (IRB00003099)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The results that we present are based on the analysis of publicly available genetic data (GWAS summary statistics) that can be found at the Psychiatric Genomics Consortium website.
